Clinical Trials Market in Russia

Summary

The Russian Clinical trials market has always enjoyed good returns since its inception, but its growth has been especially significant over the past few years, and is expected to post major growth in the future says our new report "Clinical Trials Market in Russia".

The number of Clinical trials conducted in Russia increased to 615 in 2008, which is an increase of around 9% over 2007. The country has a highly centralized healthcare system. It implies that the country has highly specialized medical units that deliver healthcare services to all the patients with common symptoms under one roof. The patients normally follow the references for the tests and treatments given by the doctors. These references are to the highly specialized doctors in the big hospitals.

The Russian Clinical Trials have been enjoying significant foreign investments and accounts for more than two-third of the total clinical trials across the world. Russia sponsored 201 clinical trials in 2008, followed by American sponsors who conducted 145 clinical trials during the year. The clinical trials conducted by Russia include various therapy areas such as oncology, cardiology, pulmonology, etc. The country has large number of physicians who are willing to work as Clinical Research Investigators, to enhance their knowledge in their fields of specialization and earn a subsidiary income.

The government is also taking vital steps to bring healthcare reforms and to encourage the Russian drug makers having well-laid plans for the development of innovative drugs, especially vaccines to compete in the market at par with the foreign players. It has recently invested US$ 3.4 Billion to improve the utilization of resources in the Russian Clinical Trials Market.

Our report is the outcome of the extensive research and thorough analysis of the Russia Clinical Trials Market. It covers the various market dynamics that play upon the performance of the Russia Clinical Trials Market. The report will also help the client to assess the future outlook of the industry based on the government initiatives, regulatory framework and the growth pattern of the pharmaceutical industry.

Contents

• 1. Analyst View
• 2. Clinical Trials Market Overview
• 3. Russian Clinical Trials Market
  • 3.1 Foreign Participation
  • 3.2 Clinical Research Outsourcing
• 4. Market Performance and Forecast
  • 4.1 Clinical Trials
  • 4.2 Global Clinical Trial Study
  • 4.3 Trials in Advanced Phases
  • 4.4 Trials under Major Therapy Areas
  • 4.5 Multi-national Sponsors
• 5. Patient Enrolment
  • 5.1 Population
  • 5.2 Disease Profile
  • 5.3 Patient Recruitment
  • 5.4 Patient Recruitment Rate
• 6. Regulatory Environment
• 7. Cost Analysis
  • 7.1 Lab Fees
  • 7.2 Hourly Rate of CRO
• 8. Clinical Trials and New Drugs Approval
  • 8.1 FDA Inspections
  • 8.2 FDA Approved Drugs
  • 8.3 EMEA Approved Drugs
• 9. Key Market Trends
• 10. Industry Restraints
• 11. Key Players
  • 11.1 Biocad
  • 11.2 Novartis
  • 11.3 Sanofi-Aventis
  • 11.4 GlaxoSmithKline plc (GSK)
  • 11.5 Pfizer
• List of Figures:
  • Figure 2-1: Share of Europe in Global Clinical Trials Market (2008)
  • Figure 2-2: European Clinical Trials Market by Player (%), 2008
  • Figure 2-3: European Clinical Research Outsourcing Market (Billion Euro) 2008 & 2012
  • Figure 2-4: Share of Eastern and Western Europe in Clinical Trials Market (2008 & 2012)
  • Figure 3-1: Share of Russian & International Sponsors in Clinical Trials (2007 & 2008)
  • Figure 3-2: Clinical Trials by Type of Operator (%)
  • Figure 4-1: Number of Clinical Trials (2005-2008)
  • Figure 4-2: Forecast for Number of Clinical Trials (2009-2012)
  • Figure 4-3: Share of Study Type in Clinical Trials (2004 to 2007)
  • Figure 4-4: Share of Study Type in Clinical Trials (2007 & 2008)
  • Figure 4-5: Number of Clinical Trials by Phase (2007 & 2008)
  • Figure 4-6: Clinical Trials by Therapy Area (%) 2007 & 2008
  • Figure 4-7: Phases of Clinical Trials by International Sponsors (Q3 2008)
  • Figure 5-1: Comparison of Population with Ukraine (Million) 2007 & 2008
  • Figure 5-2: Population Breakup by Age Group (%), 2008
  • Figure 5-3: Share of Population and Clinical Trials by Region
  • Figure 5-4: Leading Causes of Death (%) 2005 & 2030
  • Figure 5-5: Patient Recruitment by Phase of Study (%), 2008
  • Figure 8-1: Number of FDA Inspections since 1995 to 2008
  • Figure 8-2: FDA Inspection Results (%), 1995 to 2007
  • Figure 8-3: FDA Inspection Results (%), 2008
  • Figure 9-1: Qualified Specialists by Type (Thousand)
  • Figure 9-2: Urban & Rural Population Breakup (%) 2008
  • Figure 9-3: Pharmaceutical Market (Billion US$) 2007-2009
  • Figure 9-4: Forecast for Pharmaceutical Market (Billion US$), 2010-2012
• List of Tables:
  • Table 2-1: Drug Discovery, Development and Approval Process
  • Table 4-1: Number of Clinical Trials by Top Five Sponsors (2008)
  • Table 4-2: Clinical Trials by Top Five International Study Sponsors (2008)
  • Table 4-3: Clinical Trials by Top Five Russian Study Sponsors (2008)
  • Table 5-1: Patient Recruitment Rates in Top Five Therapeutic Areas
  • Table 7-1: Lab Fees Comparison with UK and US (US$)
  • Table 7-2: Fees Charged by Local CROs in Comparison to International CROs (US$/Hour)
  • Table 8-1: New Drugs Approved by FDA in Q4 2008
  • Table 8-2: New Drugs approved by EMEA in Q4 2008
  • Table 9-1: Patient Investigator Fees in Comparison to India, US and Europe (US$)
  • Table 9-2: Population and City Distribution by Federal Region
  • Table 9-3: Top Ten Emerging Cities/Region by Number of New Sites (2008)